Niki BioSolutions, Inc. (NIKI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Niki BioSolutions, Inc. (NIKI) has a cash flow conversion efficiency ratio of -0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-535.25K) by net assets ($13.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Niki BioSolutions, Inc. (NIKI) share price today for real-time trading data and today's change.
Niki BioSolutions, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Niki BioSolutions, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Niki BioSolutions, Inc. (NIKI) market capitalisation for the company's overall valuation and market capitalisation.
Niki BioSolutions, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Niki BioSolutions, Inc. ranked by their cash flow conversion efficiency. Also see NIKI total asset value for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bumi Citra Permai Tbk
JK:BCIP
|
-0.010x |
|
FENIXORO GOLD CORP.
F:8FD
|
N/A |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
0.035x |
|
Cooper Metals Ltd
AU:CPM
|
-0.020x |
|
CodeLab Capital A/S
OL:CODE
|
-0.556x |
|
UPHEALTH INC
F:5XV
|
N/A |
|
London Security Plc
LSE:LSC
|
0.108x |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
3.252x |
Annual Cash Flow Conversion Efficiency for Niki BioSolutions, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Niki BioSolutions, Inc. from 2017 to 2025. Review NIKI FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.79 Million | $-1.84 Million | -0.133x | -31.82% |
| 2024-12-31 | $11.78 Million | $-1.19 Million | -0.101x | +79.88% |
| 2023-12-31 | $15.38 Million | $-7.72 Million | -0.502x | +68.07% |
| 2022-12-31 | $7.83 Million | $-12.32 Million | -1.573x | -87.90% |
| 2021-12-31 | $17.51 Million | $-14.65 Million | -0.837x | -100.42% |
| 2020-12-31 | $38.15 Million | $-15.93 Million | -0.418x | +53.66% |
| 2019-12-31 | $14.85 Million | $-13.38 Million | -0.901x | -194.02% |
| 2018-12-31 | $32.75 Million | $-10.04 Million | -0.306x | -60.21% |
| 2017-12-31 | $30.23 Million | $-5.78 Million | -0.191x | -- |
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a r… Read more